Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo
Authors
Keywords
-
Journal
Nanomedicine
Volume 13, Issue 10, Pages 1107-1120
Publisher
Future Medicine Ltd
Online
2018-06-07
DOI
10.2217/nnm-2017-0355
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
- (2016) Zheng-Hai Tang et al. Oncotarget
- Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer
- (2015) Kai Xiao et al. BIOMATERIALS
- A Pharmacokinetic Model for Quantifying the Effect of Vascular Permeability on the Choice of Drug Carrier: A Framework for Personalized Nanomedicine
- (2015) Ameya R. Kirtane et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma
- (2015) Yaoyao Ren et al. OncoTargets and Therapy
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- (2015) Matthew J. Niederst et al. Nature Communications
- Apatinib for molecular targeted therapy in tumor
- (2015) Haijun Zhang Drug Design Development and Therapy
- Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin
- (2014) Hongyong Zhang et al. Nanomedicine
- Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
- (2014) David Cook et al. NATURE REVIEWS DRUG DISCOVERY
- In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines
- (2014) MIN-CONG WANG et al. ONCOLOGY REPORTS
- Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer
- (2014) JUN KINOSHITA et al. ONCOLOGY REPORTS
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Presentation and management of docetaxel-related adverse effects in patients with breast cancer
- (2014) Maria Ho et al. Cancer Management and Research
- Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers
- (2013) Yuanpei Li et al. ADVANCED DRUG DELIVERY REVIEWS
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Disulfide Cross-Linked Polyurethane Micelles as a Reduction-Triggered Drug Delivery System for Cancer Therapy
- (2013) Shuangjiang Yu et al. Advanced Healthcare Materials
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer
- (2012) Tzu-yin Lin et al. Nanomedicine
- EGFR Mutations and Lung Cancer
- (2011) Gilda da Cunha Santos et al. Annual Review of Pathology-Mechanisms of Disease
- Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery
- (2011) Yuanpei Li et al. BIOMATERIALS
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
- (2011) Hua Cheng et al. Journal of Hematology & Oncology
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
- (2010) Marcello Tiseo Drug Design Development and Therapy
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- Chemosensitization in non-small cell lung cancer cells by IKK inhibitor occursviaNF-κB and mitochondrial cytochrome c cascade
- (2008) Xianqing Jin et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now